As of May, 24 Ablynx NV (ABLYF) EPS Estimated At $-0.19

May 16, 2018 - By Jack Shaw

Ablynx NV (OTCMKTS:ABLYF) Corporate Logo

Ablynx NV (OTCMKTS:ABLYF)’s earnings report is anticipated by WallStreet on May, 24, as reported by Faxor. Lastly it traded at $53.3.It’s since May 16, 2017 and is 0.00% down. ABLYF underperformed the S&P 500 by 11.55%.

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases.The firm is worth $4.05 billion. The firm develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.Last it reported negative earnings. The Company’s clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: